摘要
新型冠状病毒(SARS-CoV-2)引发的急性呼吸道传染性疾病在全球大规模流行,严重威胁人类生命安全,迫切需要有效的抗新冠肺炎(COVID-19)药物。疫苗、抗体和小分子药物成为战胜疫情的关键。口服小分子药物具有成本低、易生产、方便运输等优点,已成为开发抗COVID-19特效药的焦点。近日,有两款口服小分子药物成功获批上市,用于治疗早期轻症COVID-19患者,这为全球COVID-19患者的治疗和预防打了一剂强效“加强针”。鉴于此,本研究基于当前口服小分子药物研究和发展现状,简要梳理了治疗COVID-19口服小分子药物的开发策略,挑选目前已上市或正处于临床试验的治疗COVID-19口服小分子药物,总结其临床治疗效果、作用特点及作用机制,以期为口服小分子抗COVID-19药物的开发提供一定参考。
Corona virus disease 2019(COVID-19)caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)are spreading globally on a large scale,seriously threatening the safety of human life,and the world urgently needs effective against COVID-19 drugs.Vaccines,antibodies and small molecule drugs have become the key to defeating the epidemic of COVID-19.Due to the low cost,easy production,and convenient transportation of oral small molecule drugs,they have become the focus of the development of sovereign remedy to ultimately defeat the COVID-19.Recently,two oral small molecule drugs have been successfully approved for market to treat patients with early mild COVID-19.This is a powerful"strengthening shot"for the treatment and prevention of COVID-19.This paper briefly summarizes the current anti-coronavirus oral small molecule drug development strategies,and selects the most representative and promising oral small molecule drugs,reviews their clinical therapeutic effects,characteristics of action,and mode of action,to provide some references for the development of novel oral small molecule anti-coronavirus drugs.
作者
卞金磊
张立翱
徐熙
李志裕
BIAN Jinlei;ZHANG Li′ao;XU Xi;LI Zhiyu(China Pharmaceutical University,Jiangsu Nanjing 211198,China)
出处
《中国医药导刊》
2022年第1期16-26,共11页
Chinese Journal of Medicinal Guide
基金
中国药科大学抗新型冠状病毒肺炎感染应急科研专项[项目编号:2632020ZX001
项目名称:防治新型冠状病毒肺炎瑞德西韦(Remdesivir)的合成工艺研究及针对NSP12及3CLpro开发抗新型冠状病毒肺炎的创新小分子药物研发]。
